Recent 8-K filings for ONCO

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 14, 2026 00:35 UTC other_material item 8.01item 9.01

  Onconetix reports Q1 2026 progress: two Proclarix publications, PRIME study with Labcorp, European expansion

• May 04, 2026 23:59 UTC other_material item 5.07item 9.01

  Onconetix shareholders approve reverse stock split up to 1-for-10

• Apr 24, 2026 23:59 UTC leadership item 5.02item 9.01

  Onconetix board: Oakley and Meier resign; Dorf named Chairman; Epstein elected director

• Mar 27, 2026 23:59 UTC other_material item 5.03item 8.01item 9.01

  Onconetix implements 1-for-5 reverse stock split to maintain Nasdaq compliance

• Mar 25, 2026 23:59 UTC leadership item 5.02item 9.01

  Onconetix appoints David White CEO, Sammy Dorf to board; Ramdeen resigns

• Mar 24, 2026 23:59 UTC leadership item 5.02item 9.01

  Onconetix appoints David White CEO, adds Sammy Dorf to board

• Feb 12, 2026 23:59 UTC m_and_a item 1.01item 8.01item 9.01

  Onconetix to acquire Realbotix in reverse merger; Realbotix holders to own 75-90%

• Feb 09, 2026 23:59 UTC other_material item 5.07item 9.01

  Onconetix shareholders approve reverse stock split (1:2 to 1:50) at special meeting

• Dec 10, 2025 23:59 UTC other_material item 1.01item 9.01

  Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix

• Dec 10, 2025 23:59 UTC other_material item 5.02item 5.07item 9.01

  Onconetix boosts interim CEO pay; shareholders OK PIPE issuance for up to 12.8M shares

• Oct 29, 2025 23:59 UTC other item 5.08

  Onconetix fixes 2025 annual meeting for Dec 5; shareholder submissions due Nov 10

• Oct 03, 2025 23:59 UTC other_material item 1.01item 3.02item 9.01

  Onconetix secures $6.25M through PIPE of Series E convertible preferred and warrants

• Sep 26, 2025 23:59 UTC other_material item 1.01item 1.02item 3.02item 7.01item 9.01

  Onconetix raises $12.9M via Series D convertible preferred stock and warrants in PIPE financing

• Sep 22, 2025 23:59 UTC other item 1.01item 7.01item 9.01

  Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia

• Sep 04, 2025 23:59 UTC debt item 1.01item 2.03item 9.01

  Onconetix issues $117.6K in promissory notes; amends Veru note to $5.2M, extended to Sept 19

• Aug 12, 2025 23:59 UTC debt item 1.01item 2.03item 5.02item 9.01

  Onconetix issues $118K Keystone note, extends Veru note to Aug 14, 2025; director resigns

• Jul 16, 2025 23:59 UTC m_and_a item 1.01item 5.02item 8.01item 9.01

  Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company

source · ONCO on sec.gov